Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Antineoplastic Agents
  • Protein-Tyrosine Kinases
  • Proto-Oncogene Proteins c-ret
  • Pyridines

abstract

  • Cabozantinib has an acceptable safety profile and is active in MTC. Cabozantinib may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including MET, VEGFR2, and RET. A global phase III pivotal study in MTC is ongoing (ClinicalTrials.gov number NCT00215605).

publication date

  • July 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3646303

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.4145

PubMed ID

  • 21606412

Additional Document Info

start page

  • 2660

end page

  • 6

volume

  • 29

number

  • 19